Bedaquiline reprograms central metabolism to reveal glycolytic vulnerability in Mycobacterium tuberculosis

The approval of bedaquiline (BDQ) for the treatment of tuberculosis has generated substantial interest in inhibiting energy metabolism as a therapeutic paradigm. However, it is not known precisely how BDQ triggers cell death in Mycobacterium tuberculosis (Mtb). Using (13)C isotopomer analysis, we sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Mackenzie, Jared S., Lamprecht, Dirk A., Asmal, Rukaya, Adamson, John H., Borah, Khushboo, Beste, Dany J. V., Lee, Bei Shi, Pethe, Kevin, Rousseau, Simon, Krieger, Inna, Sacchettini, James C., Glasgow, Joel N., Steyn, Adrie J. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705017/
https://www.ncbi.nlm.nih.gov/pubmed/33257709
http://dx.doi.org/10.1038/s41467-020-19959-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705017/
https://www.ncbi.nlm.nih.gov/pubmed/33257709
http://dx.doi.org/10.1038/s41467-020-19959-4

Ejemplares similares